Goldman Sachs Downgrades Emerson (EMR) to Neutral Citing Lack of Catalysts

Goldman Sachs downgraded Emerson (NYSE: EMR) from Buy to Neutral with a price target of $54 citing a lack of near-term catalysts.

Despite an above-average dividend yield, strong free cash flow, low sentiment and 2011 underperformance, "EMR shares may struggle to outperform until a resumption of estimate revision momentum re-emerges, which could take several quarters."

For an analyst ratings summary and ratings history on Emerson click here. For more ratings news on Emerson click here.

Shares of Emerson closed at $48.70 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Piper Sandler Double Downgrades Myriad Genetics (MYGN) to Underweight, 'Major Strategic Action Likely Needed'
• JPMorgan Downgrades Huaxia Bank Co Ltd (600015:CH) to Underweight
• CLSA Downgrades Samsung Biologics (207940:KS) to Outperform (2)